Share on StockTwits
 

Salix Pharmaceuticals (NASDAQ:SLXP)‘s stock had its “neutral” rating reaffirmed by Zacks in a research report issued to clients and investors on Monday, AnalystRatingsNetwork.com reports. They currently have a $103.00 price objective on the stock. Zacks‘ price objective would indicate a potential upside of 4.50% from the company’s current price.

Zacks‘ analyst wrote, “Salix posted third quarter 2013 EPS of $0.80, above the year-ago EPS of $0.69 but below the Zacks Consensus Estimate of $0.95. Revenues increased 29% to $238.2 million, in-line with the Zacks Consensus Estimate. We are positive on Salix’ acquisition of Santarus, which has expanded Salix’ product portfolio as well as pipeline and will strengthen its position in the gastrointestinal market. With the addition of marketed products like Uceris, Glumetza and Zegerid, Salix’ product offering and revenue base has diversified. The Santarus acquisition will be significantly accretive in 2014. Additional synergies will lead to higher EPS accretion in 2015. We expect investor focus to remain on updates on Relistor and data from TARGET-3. We remain Neutral on the stock.”

In other Salix Pharmaceuticals news, Director Alonzo Thomas D sold 12,050 shares of the company’s stock on the open market in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $91.83, for a total transaction of $1,106,551.50. Following the transaction, the director now directly owns 97,974 shares of the company’s stock, valued at approximately $8,996,952. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Salix Pharmaceuticals (NASDAQ:SLXP) traded up 2.21% during mid-day trading on Monday, hitting $98.56. The stock had a trading volume of 731,909 shares. Salix Pharmaceuticals has a 1-year low of $45.86 and a 1-year high of $99.24. The stock’s 50-day moving average is $88.62 and its 200-day moving average is $76.01. The company has a market cap of $6.199 billion and a price-to-earnings ratio of 57.30.

Salix Pharmaceuticals (NASDAQ:SLXP) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.86 by $0.03. The company had revenue of $238.20 million for the quarter, compared to the consensus estimate of $239.70 million. During the same quarter in the previous year, the company posted $0.95 earnings per share. The company’s revenue for the quarter was up 28.7% on a year-over-year basis. On average, analysts predict that Salix Pharmaceuticals will post $3.22 earnings per share for the current fiscal year.

SLXP has been the subject of a number of other recent research reports. Analysts at Leerink Swann raised their price target on shares of Salix Pharmaceuticals to $115.00 in a research note to investors on Friday. Separately, analysts at Mizuho raised their price target on shares of Salix Pharmaceuticals from $101.00 to $127.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Brean Capital raised their price target on shares of Salix Pharmaceuticals from $90.00 to $108.00 in a research note to investors on Tuesday, January 14th. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $88.63.

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.